Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program

Catherine Kim, Dana Dabelea, Rita R. Kalyani, Costas A. Christophi, George A. Bray, Xavier Pi-Sunyer, Christine H. Darwin, Swaytha Yalamanchi, Elizabeth Barrett-Connor, Sherita Hill Golden, Edward J. Boyko

Research output: Contribution to journalArticle

Abstract

Context: The degree to which changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) relate to corresponding changes in plasma sex steroids is not known.

Objective: We examined whether changes in VAT and SAT areas assessed by computed tomography were associated with changes in sex hormones [dehydroepiandrosterone sulfate (DHEAS), testosterone, estradiol, estrone, and sex hormone binding globulin (SHBG)] among Diabetes Prevention Program participants.

Design: Secondary analysis of a randomized trial.

Participants: Overweight and glucose-intolerant men (n = 246) and women (n = 309).

Interventions: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise or metformin administered 850 mg twice a day or placebo.

Main Outcome Measures: Associations between changes in VAT, SAT, and sex hormone changes over 1 year.

Results: Among men, reductions in VAT and SAT were both independently associated with significant increases in total testosterone and SHBG in fully adjusted models. Among women, reductions in VAT and SAT were both independently associated with increases in SHBG and associations with estrone differed by menopausal status. Associations were similar by race/ethnicity and by randomization arm. No significant associations were observed between change in fat depot with change in estradiol or DHEAS.

Conclusions: Among overweight adults with impaired glucose intolerance, reductions in either VAT and SAT were associated with increased total testosterone in men and higher SHBG in men and women. Weight loss may affect sex hormone profiles via reductions in visceral and subcutaneous fat.

Original languageEnglish (US)
Pages (from-to)3381-3389
Number of pages9
JournalThe Journal of clinical endocrinology and metabolism
Volume102
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Intra-Abdominal Fat
Subcutaneous Fat
Adiposity
Gonadal Steroid Hormones
Medical problems
Sex Hormone-Binding Globulin
Tissue
Testosterone
Dehydroepiandrosterone Sulfate
Estrone
Weight Loss
Glucose Intolerance
Metformin
Random Allocation
Fats
Life Style
Estradiol
Glucose
Steroids
Tomography

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program. / Kim, Catherine; Dabelea, Dana; Kalyani, Rita R.; Christophi, Costas A.; Bray, George A.; Pi-Sunyer, Xavier; Darwin, Christine H.; Yalamanchi, Swaytha; Barrett-Connor, Elizabeth; Golden, Sherita Hill; Boyko, Edward J.

In: The Journal of clinical endocrinology and metabolism, Vol. 102, No. 9, 01.09.2017, p. 3381-3389.

Research output: Contribution to journalArticle

Kim, C, Dabelea, D, Kalyani, RR, Christophi, CA, Bray, GA, Pi-Sunyer, X, Darwin, CH, Yalamanchi, S, Barrett-Connor, E, Golden, SH & Boyko, EJ 2017, 'Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program', The Journal of clinical endocrinology and metabolism, vol. 102, no. 9, pp. 3381-3389. https://doi.org/10.1210/jc.2017-00967
Kim, Catherine ; Dabelea, Dana ; Kalyani, Rita R. ; Christophi, Costas A. ; Bray, George A. ; Pi-Sunyer, Xavier ; Darwin, Christine H. ; Yalamanchi, Swaytha ; Barrett-Connor, Elizabeth ; Golden, Sherita Hill ; Boyko, Edward J. / Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program. In: The Journal of clinical endocrinology and metabolism. 2017 ; Vol. 102, No. 9. pp. 3381-3389.
@article{cfe0b864d9a1429f967c4f7bdb8b701e,
title = "Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program",
abstract = "Context: The degree to which changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) relate to corresponding changes in plasma sex steroids is not known.Objective: We examined whether changes in VAT and SAT areas assessed by computed tomography were associated with changes in sex hormones [dehydroepiandrosterone sulfate (DHEAS), testosterone, estradiol, estrone, and sex hormone binding globulin (SHBG)] among Diabetes Prevention Program participants.Design: Secondary analysis of a randomized trial.Participants: Overweight and glucose-intolerant men (n = 246) and women (n = 309).Interventions: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise or metformin administered 850 mg twice a day or placebo.Main Outcome Measures: Associations between changes in VAT, SAT, and sex hormone changes over 1 year.Results: Among men, reductions in VAT and SAT were both independently associated with significant increases in total testosterone and SHBG in fully adjusted models. Among women, reductions in VAT and SAT were both independently associated with increases in SHBG and associations with estrone differed by menopausal status. Associations were similar by race/ethnicity and by randomization arm. No significant associations were observed between change in fat depot with change in estradiol or DHEAS.Conclusions: Among overweight adults with impaired glucose intolerance, reductions in either VAT and SAT were associated with increased total testosterone in men and higher SHBG in men and women. Weight loss may affect sex hormone profiles via reductions in visceral and subcutaneous fat.",
author = "Catherine Kim and Dana Dabelea and Kalyani, {Rita R.} and Christophi, {Costas A.} and Bray, {George A.} and Xavier Pi-Sunyer and Darwin, {Christine H.} and Swaytha Yalamanchi and Elizabeth Barrett-Connor and Golden, {Sherita Hill} and Boyko, {Edward J.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1210/jc.2017-00967",
language = "English (US)",
volume = "102",
pages = "3381--3389",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Changes in Visceral Adiposity, Subcutaneous Adiposity, and Sex Hormones in the Diabetes Prevention Program

AU - Kim, Catherine

AU - Dabelea, Dana

AU - Kalyani, Rita R.

AU - Christophi, Costas A.

AU - Bray, George A.

AU - Pi-Sunyer, Xavier

AU - Darwin, Christine H.

AU - Yalamanchi, Swaytha

AU - Barrett-Connor, Elizabeth

AU - Golden, Sherita Hill

AU - Boyko, Edward J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Context: The degree to which changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) relate to corresponding changes in plasma sex steroids is not known.Objective: We examined whether changes in VAT and SAT areas assessed by computed tomography were associated with changes in sex hormones [dehydroepiandrosterone sulfate (DHEAS), testosterone, estradiol, estrone, and sex hormone binding globulin (SHBG)] among Diabetes Prevention Program participants.Design: Secondary analysis of a randomized trial.Participants: Overweight and glucose-intolerant men (n = 246) and women (n = 309).Interventions: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise or metformin administered 850 mg twice a day or placebo.Main Outcome Measures: Associations between changes in VAT, SAT, and sex hormone changes over 1 year.Results: Among men, reductions in VAT and SAT were both independently associated with significant increases in total testosterone and SHBG in fully adjusted models. Among women, reductions in VAT and SAT were both independently associated with increases in SHBG and associations with estrone differed by menopausal status. Associations were similar by race/ethnicity and by randomization arm. No significant associations were observed between change in fat depot with change in estradiol or DHEAS.Conclusions: Among overweight adults with impaired glucose intolerance, reductions in either VAT and SAT were associated with increased total testosterone in men and higher SHBG in men and women. Weight loss may affect sex hormone profiles via reductions in visceral and subcutaneous fat.

AB - Context: The degree to which changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) relate to corresponding changes in plasma sex steroids is not known.Objective: We examined whether changes in VAT and SAT areas assessed by computed tomography were associated with changes in sex hormones [dehydroepiandrosterone sulfate (DHEAS), testosterone, estradiol, estrone, and sex hormone binding globulin (SHBG)] among Diabetes Prevention Program participants.Design: Secondary analysis of a randomized trial.Participants: Overweight and glucose-intolerant men (n = 246) and women (n = 309).Interventions: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise or metformin administered 850 mg twice a day or placebo.Main Outcome Measures: Associations between changes in VAT, SAT, and sex hormone changes over 1 year.Results: Among men, reductions in VAT and SAT were both independently associated with significant increases in total testosterone and SHBG in fully adjusted models. Among women, reductions in VAT and SAT were both independently associated with increases in SHBG and associations with estrone differed by menopausal status. Associations were similar by race/ethnicity and by randomization arm. No significant associations were observed between change in fat depot with change in estradiol or DHEAS.Conclusions: Among overweight adults with impaired glucose intolerance, reductions in either VAT and SAT were associated with increased total testosterone in men and higher SHBG in men and women. Weight loss may affect sex hormone profiles via reductions in visceral and subcutaneous fat.

UR - http://www.scopus.com/inward/record.url?scp=85031026486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031026486&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-00967

DO - 10.1210/jc.2017-00967

M3 - Article

C2 - 28651370

AN - SCOPUS:85031026486

VL - 102

SP - 3381

EP - 3389

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -